Maze Therapeutics SVP Finance Amy Bachrodt resigns, CFO to assume accounting role

Filed May 22, 2026 · Period ending May 18, 2026 · ~1 min read

Key Changes

• medium

  Amy Bachrodt, Senior Vice President of Finance, resigned effective June 1, 2026. The company states her departure is not due to any disagreement on operations, policies, or financial reporting.

  Item 5.02 verify on EDGAR →
• low

  CFO Misbah Tahir will assume the principal accounting officer role following Bachrodt's departure, consolidating financial leadership under one executive.

  Item 5.02 verify on EDGAR →